Rebound Macular Edema Following Bevacizumab (Avastin) Therapy for Retinal Venous Occlusive Disease

Matsumoto, Yōko; Freund, K. Bailey; Peiretti, Enrico; Cooney, Michael J.; Ferrara, Daniela; Yannuzzi, Lawrence A.

doi:10.1097/iae.0b013e31804a7af2

Cited by 115 publications

(64 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…16 Macular grid laser was given to all our patients to counter macula edema, which was the main cause of vision loss, and also the reason for reappearance of macular edema was the main indication for requirement of repeated injections. In CVOS, eyes with perfused macular edema on FFA and a visual acuity of 20/50 or worse were randomized to treatment with macular grid laser photocoagulation or observation only (no treatment).…”

Section: Discussionmentioning

confidence: 99%

Long-term effect of early intervention with single intravitreal injection of bevacizumab followed by panretinal and macular grid photocoagulation in central retinal vein occlusion (CRVO) with macular edema: A pilot study

Shah

2011

Eye

View full text Add to dashboard Cite

Purpose To evaluate the effect of single-dose intravitreal bevacizumab followed by panretinal and macular grid laser, early in the course of central retinal vein occlusion (CRVO). Methods It is a prospective, non-randomized, interventional study of nine eyes of nine patients with o10 days origin of CRVO who received 2.5 mg (0.1 ml) intravitreal bevacizumab, followed 3 weeks later by panretinal and macular grid photocoagulation. Its effect on visual acuity and anatomical features of CRVO were studied. Results Nine eyes of nine patients (male : female ¼ 8 : 1, mean age 54 years), with o10days (average 2.67days) onset of CRVO, received intravitreal bevacizumab within 7 days of presentation (average 3.1days) followed 3 weeks later by panretinal with macular grid laser. Presenting mean baseline visual acuity was 20/320 (1.2 logarithm of the minimum angle of resolution (LOGMAR) units). All the patients showed rapid improvement in the form of rapid clearance of retinal hemorrhages, decreased optic disc swelling and venous dilation, and tortuosity. Mean final visual acuity was 20/63 (0.5 LOGMAR units). No patient showed conversion from non-ischemic to ischaemic CRVO, recurrence of macular edema, and disc collateral formation. Conclusion Early intravitreal bevacizumab followed by panretinal and macular grid laser may provide visually and anatomically favourable results in a case of CRVO. It may also obviate the need for repeated injection. It requires a large randomized study to substantiate the results.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term effect of early intervention with single intravitreal injection of bevacizumab followed by panretinal and macular grid photocoagulation in central retinal vein occlusion (CRVO) with macular edema: A pilot study

Shah

2011

Eye

View full text Add to dashboard Cite

show abstract

“…12 Matsumoto et al also reported that rebound macular edema was observed following intravitreal bevacizumab in patients with retinal vein occlusion of a chronic nature. 19 The authors hypothesized that bevacizumabinduced upregulation of VEGF receptors may be more sensitive to the VEGF in the underlying ischemic state. 19 The onset of recurrent retinal NV varied among our patients.…”

Section: Figmentioning

confidence: 99%

“…19 The authors hypothesized that bevacizumabinduced upregulation of VEGF receptors may be more sensitive to the VEGF in the underlying ischemic state. 19 The onset of recurrent retinal NV varied among our patients. In the current study, we chose to defer the reinjection only when recurrent NV occurred.…”

Section: Figmentioning

confidence: 99%

Intravitreal Bevacizumab (Avastin) and Panretinal Photocoagulation in the Treatment of High-Risk Proliferative Diabetic Retinopathy

Yang

Hung

Huang

et al. 2013

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

Purpose: To report the short-term efficacy and safety of intravitreal bevacizumab (Avastin) injection with panretinal laser photocoagulation (PRP) in patients with high-risk proliferative diabetic retinopathy (PDR) according to the Early Treatment Diabetic Retinopathy Study criteria. Methods: A prospective, interventional case series study was conducted in 17 patients (20 eyes) with high-risk PDR, who were treated with intravitreal bevacizumab (2.5 mg) followed by PRP when the peripheral vitreous became clear or 2 weeks after injection. Patients underwent complete ophthalmic evaluation, including Snellen visual acuity and fluorescein angiography at baseline, 1, 3, and 6 months after bevacizumab injection. Main outcome measures included the serial changes in visual acuity, vitreous clear-up time, and neovascularization on the disc (NVD) regression time. Results: All patients had obvious reduction in angiographic leakage and involution of retinal neovascularization (NV) at the 1-and 3-month follow-up. The mean follow-up time was 7.5 months. The vitreous hemorrhage (VH) showed a partial resolution as early as 1 week, and complete regression at 3 months. The mean vitreous clear-up time after intravitreal Avastin was 8.5 -2.2 weeks. The mean time interval from intravitreal Avastin to NVD regression was 10.8 -3.4 weeks. Mean logarithm of the minimum angle resolution visual acuity improved from 1.03 at baseline to 0.36 at 1-month, 0.38 at 3-month, and 0.48 at the 6-month follow-up (P < 0.01). Three eyes (18%) required vitrectomy surgery during follow-up. The indication for vitrectomy was dense, persistent VH in 2 eyes, and focal tractional retinal detachment (TRD) in 1 eye. Recurrent retinal NV with minor preretinal hemorrhage was observed in 6 eyes (30%) 3 months after the first injection, and resolved after repeated bevacizumab injections. Patients received an average of 1.4 injections (range: 1-2). Seven eyes (35%) underwent 2 injections. One eye (5%) had ocular complication of PDR progression to TRD. No systemic adverse events were observed following injections. Conclusions: Short-term results suggest combined intravitreal bevacizumab and PRP achieved rapid clearance of VH, regression of retinal NV, and visual improvement in the treatment of high-risk PDR. Long-term study is warranted to assess the long-term efficacy and safety.

show abstract

“…Rebound in tumor growth and revascularization were previously documented in mice [1]. Furthermore, rebound following angiogenesis inhibitors' interruption has also been described in the care of retinopathies [4]. Hence, BV might disregulate the balance between pro-and antiangiogenic signals, so that the proangiogenic one is broadly over-represented after BV withdrawal.…”

mentioning

confidence: 99%

Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery

Cacheux

Boisserie²,

Staudacher

et al. 2008

Annals of Oncology

View full text Add to dashboard Cite

show abstract

Rebound Macular Edema Following Bevacizumab (Avastin) Therapy for Retinal Venous Occlusive Disease

Cited by 115 publications

References 10 publications

Long-term effect of early intervention with single intravitreal injection of bevacizumab followed by panretinal and macular grid photocoagulation in central retinal vein occlusion (CRVO) with macular edema: A pilot study

Long-term effect of early intervention with single intravitreal injection of bevacizumab followed by panretinal and macular grid photocoagulation in central retinal vein occlusion (CRVO) with macular edema: A pilot study

Intravitreal Bevacizumab (Avastin) and Panretinal Photocoagulation in the Treatment of High-Risk Proliferative Diabetic Retinopathy

Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery

Contact Info

Product

Resources

About